Comparative Evaluation of the Effectiveness of Nivolumab Versus Axitinib in the Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma: A Two-Center Experience. (PubMed, J Clin Med) - Sep 27, 2026 - "However, the retrospective design, small sample size, imbalance in treatment allocation and nephrectomy rates, and potential residual confounding limit causal interpretation. Prospective studies are warranted to confirm these findings."
Journal • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
Metin Özkan; Oktay Bozkurt
|